Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung.

Detailed description of study

The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung cancer
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Pathological diagnosis of squamous cell carcinoma of the lung
Exclusion Criteria
Previous radiation therapy to the lung per investigator discretion

Updated on 04 Aug 2024. Study ID: 1706985235 (IUSCC-0624)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team